LB Pharmaceuticals Inc Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LBRX research report →
Range $36 – $78
Price Chart
About the company
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
- CEO
- Heather D. Turner
- IPO
- 2025
- Employees
- 49
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on LBRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.37B
- P/E
- -16.04
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 4.32
- EV/EBITDA
- -12.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -25.91%
- ROIC
- -28.07%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-30,404,000
- Net Income
- $-25,205,000+60.1%
- EPS
- $-1.00+94.4%
- OCF Growth
- +33.6%
- FCF Growth
- +34.5%
- 52W High
- $49.97
- 52W Low
- $13.36
- 50D MA
- $36.04
- 200D MA
- $26.75
- Beta
- 0.42
- RSI (14)
- 65
- Avg Volume
- 322.67K
No earnings-call transcripts are available for LBRX yet.
- Free Float
- 72.4%
- Shares Outstanding
- 28.68M
- Float Shares
- 20.76M
of shares held by institutions
77 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deep Track Capital, LP | 3.35M | 0 |
| Blackrock, Inc. | 2.73M | ▲ 263.46K |
| Ra Capital Management, L.P. | 2.21M | 0 |
| Commodore Capital LP | 1.50M | 0 |
| Jpmorgan Chase & Co | 1.50M | ▲ 69.72K |
| Tcg Crossover Management, LLC | 1.45M | ▼ 392.18K |
| Caligan Partners LP | 1.44M | 0 |
| Vanguard Group Inc | 1.11M | ▲ 1.11M |
| Nantahala Capital Management, LLC | 1.05M | 0 |
| Vanguard Capital Management LLC | 971.16K | ▲ 76.51K |
| Balyasny Asset Management L.P. | 921.47K | ▼ 2.22K |
| Alyeska Investment Group, L.P. | 863.95K | 0 |
Held by 131 ETFs
Biggest fund positions in LBRX by dollar value.
Our LBRX coverage
Recent articles, reports, and earnings notes.
No research on LBRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LBRX report →Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
seekingalpha.com · Aug 16
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 11
LB Pharmaceuticals Announces $150 Million Private Placement
globenewswire.com · Jul 29
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
globenewswire.com · Jul 22
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 10
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
globenewswire.com · Jun 30
LB Pharmaceuticals to Participate in Upcoming June Investor Events
globenewswire.com · May 28
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
zacks.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.